NASDAQ · NGNE
Neurogene Inc.
$28.82-$1.60 (-5.26%)
Neurogene Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.99% below the high.
Loading market information…
OTC · NDTP · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
NDT Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.24% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow NDT Pharmaceuticals Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
NDT Pharmaceuticals Inc., a biotechnology firm situated in Vienna, Virginia, is dedicated to formulating a range of treatments for serious neurological ailments, particularly those stemming from traumatic brain injuries.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$28.82-$1.60 (-5.26%)
Neurogene Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.99% below the high.
$2.24-$0.01 (-0.44%)
Alector, Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.84% below the high.
$2.24+$0.03 (+1.36%)
Minerva Neurosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.55% below the high.
$3.12+$0.09 (+2.97%)
Neonc Technologies Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.0% below the high.
$0.39-$0.00 (-1.22%)
Neumora Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 89.36% below the high.
A$0.27+A$0.01 (+1.92%)
Alterity Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 66.24% below the high.
$0.25$0.00 (0.0%)
Biomind Labs Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.73% below the high.
$3.06-$0.30 (-8.93%)
Neuphoria Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.67% below the high.
